Joining FORCES is the FORCE newsletter with news, views and supportive information for individuals concerned about hereditary breast and ovarian cancer.
On June 25, the Oncologic Drugs Advisory Committee (ODAC) of the FDA will discuss AstraZeneca Pharmaceuticals — new drug application for olaparib (a PARP inhibitor) capsules as maintenance treatment of patients with platinumsensitive relapsed ovarian cancer who have completed chemotherapy. The public meeting will take place at the FDA offices outside of Washington, D.C. PARP inhibitors were developed specifically for the treatment of cancers associated with a BRCA genetic mutation.
FORCE has been a strong proponent of PARP inhibitor research, and we will present oral commentary supporting approval of this application. We are hopeful that olaparib will be approved as a new agent for women fighting hereditary ovarian cancer.